2019
DOI: 10.15171/apb.2019.031
|View full text |Cite
|
Sign up to set email alerts
|

Omega-3 Fatty Acid Based Nanolipid Formulation of Atorvastatin for Treating Hyperlipidemia

Abstract: Purpose: In the current study, attempts have been made to formulate an omega-3 fatty acid based nanostructured lipid carriers of atorvastatin (AT), for treating hyperlipidemia; and to evaluate their antihyperlipidemic activity using in vitro and in vivo studies. Methods: Omega-3 fatty acid based AT-loaded nanolipid carriers (NLC) were formulated by the melt emulsification ultrasonication technology. The prepared NLC consist of stearic acid (as solid lipid), omega-3 fatty acid (as liquid lipid), Tween 80, polo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
10
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
1
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 23 publications
(10 citation statements)
references
References 38 publications
0
10
0
Order By: Relevance
“…The accelerated stability study was carried out to determine the shelf life of the CO-NLCs [ 28 ]. The samples were kept in tightly sealed glass bottles and stored at two different temperatures and ambient humidity conditions (30 °C/60% and 40 °C/75%) for a period of 3 months.…”
Section: Methodsmentioning
confidence: 99%
“…The accelerated stability study was carried out to determine the shelf life of the CO-NLCs [ 28 ]. The samples were kept in tightly sealed glass bottles and stored at two different temperatures and ambient humidity conditions (30 °C/60% and 40 °C/75%) for a period of 3 months.…”
Section: Methodsmentioning
confidence: 99%
“…Melt-Emulsification combined with Ultrasonica tion Method was recently reported (Sreedhar et al, 2019). Fig.…”
Section: Methods Of Preparationmentioning
confidence: 99%
“…Another study conducted by a separate group in 2019 focused on utilizing Atorvastatin (Caplin Point Laboratories Ltd., Pondicherry, India) nano lipid carriers preloaded with ω-3-PUFA (Triomega, Sanofi India Ltd., Mumbai, India) to lower hyperlipidemia. When compared with the commercial formulation, orally administered ω-3-FA based AT preloaded nano lipid carriers resulted in a substantial decrease in low-density lipoprotein and triglyceride levels in the blood [106]. Through various studies, nanoencapsulation has been shown to increase the bioavailability of ω-3-PUFAs in the body.…”
Section: Nano-encapsulation Of Omega-3 Pufamentioning
confidence: 99%